Evidence map›Paper›PMID 38884947›Full record

ReviewPharmacogenomics2024

A critical review of RAF inhibitors in BRAF-mutated glioma treatment.

John-Victor El Khoury, Sophie Wehbe, Fouad Attieh, Marc Boutros, Carole Kesrouani, Hampig Raphaël Kourie

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacogenomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

John-Victor El KhouryUniversité Saint-Joseph de Beyrouth, Beyrouth, 11-5076, Lebanon.ORCID 0009-0008-1467-9938
Sophie WehbeUniversité Saint-Joseph de Beyrouth, Beyrouth, 11-5076, Lebanon.ORCID 0009-0009-3749-1062
Fouad AttiehUniversité Saint-Joseph de Beyrouth, Beyrouth, 11-5076, Lebanon.ORCID 0000-0002-2599-5521
Marc BoutrosUniversité Saint-Joseph de Beyrouth, Beyrouth, 11-5076, Lebanon.ORCID 0000-0003-1765-4222
Carole KesrouaniDepartment of Pathology, Université Saint-Joseph de Beyrouth, Beyrouth, 11-5076, Lebanon.ORCID 0000-0003-0915-3954
Hampig Raphaël KourieDepartment of Hematology-Oncology, Université Saint-Joseph de Beyrouth, Beyrouth, 11-5076, Lebanon.ORCID 0000-0002-2502-5402

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRAF gliomas have garnered significant attention in research due to the lack of effective treatments and their notable incidence, constituting 3% of all gliomas. This underlines the importance of investigating this area and the impact that targeted therapies could hold. This review discusses the development of targeted therapies for these tumors, examining the effectiveness of first-generation BRAF inhibitors such as Vemurafenib, Dabrafenib and Encorafenib, while addressing the challenges posed by paradoxical ERK activation. The advent of pan-RAF inhibitors, notably Tovorafenib, offers a promising advance, demonstrating enhanced efficacy and better penetration of the blood-brain barrier, without the issue of paradoxical activation. Nevertheless, continued research is essential to refine therapeutic strategies for BRAF-mutated gliomas, given the evolving nature of targeted therapy development.

Indexed as

Brain NeoplasmsGliomaMutationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafAntineoplastic AgentsHumansMolecular Targeted TherapyAntineoplastic AgentsBRAF protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Identifiers

PMID38884947
PMCPMC11404696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.